Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome (AUTOREST)

This study has been completed.
University Hospital Inselspital, Berne
Cardiocentro Ticino
Information provided by (Responsible Party):
Mauro Manconi, Ospedale Regionale di Lugano Identifier:
First received: December 23, 2013
Last updated: January 23, 2017
Last verified: January 2017
The purpose of this study is to explore whether patients with restless legs syndrome (RLS) differ from healthy subjects in daytime and night time autonomic function and cardiovascular risk markers and whether 4 week treatment with pramipexole affects autonomic function and cardiovascular risk markers in patients with RLS.

Condition Intervention Phase
Restless Legs Syndrome
Drug: Pramipexole
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Other
Official Title: Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome: AUTOREST, a Case-control Study and a Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week, Multicenter Study of 0.25mg Pramipexole vs. Placebo in Patients With RLS

Resource links provided by NLM:

Further study details as provided by Mauro Manconi, Ospedale Regionale di Lugano:

Primary Outcome Measures:
  • Change in heart rate activations during sleep from baseline to 4 weeks [ Time Frame: Baseline, Week 4 ]
    Number and amplitude of periodic leg movements during sleep (PLMS) and non-PLMS related heart rate activations during stable nocturnal sleep

Secondary Outcome Measures:
  • Change in baroreflex from baseline to 4 weeks [ Time Frame: Baseline, Week 4 ]
    Baroreflex sensitivity and baroreflex gain derived from tilt table tes

  • Change in blood serum markers from baseline to 4 weeks [ Time Frame: Baseline, Week 4 ]
    Highly-sensitive C reactive protein (hsCRP), lipoprotein-associated phospholipase A2 (lP-PLA2), and oxidised low density lipoprotein (oxLDL)

Other Outcome Measures:
  • Change in chemoreflexes from baseline to 4 weeks [ Time Frame: Baseline, Week 4 ]
    Peripheral and central chemoreflex sensitivity derived from carbon dioxide (CO2) rebreathing test

Enrollment: 20
Study Start Date: December 2013
Study Completion Date: December 31, 2016
Primary Completion Date: December 31, 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Pramipexole
Pramipexole, 0.25 mg, daily for 4 weeks
Drug: Pramipexole
Placebo Comparator: Placebo
Placebo, daily for 4 weeks
Drug: Placebo


Ages Eligible for Study:   30 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria (all participants):

  • Willingness to participate and written informed consent
  • Aged 30 to 65 years at the time of screening
  • Body mass index (BMI) ≤ 30
  • Unremarkable neurological and physical examination
  • Unremarkable standard blood parameter according to local reference values

Additional Inclusion Criteria for Restless Legs Syndrome (RLS) Patients:

  • RLS according to current standard international criteria
  • RLS symptoms ≥ 2 times per week for ≥ 1 year and during the past 12 months.
  • Either current international RLS severity scale (IRLS) ≥ 15 or current IRLS ≥ 10 and RLS symptoms ≥ 4 times per week during the past 3 months.

Exclusion Criteria (all participants):

  • Pregnancy, or breast feeding at time of screening.
  • Recent anaesthesia (last 3 months).
  • Sleep related breathing disorders during nocturnal polysomnography:
  • Current history of psychiatric disorders according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV).
  • Life time history of any diagnosis of, medication or intervention for cardiovascular diseases.
  • Current chronic treatment that may affect autonomic function.
  • Any significant neurological disease or diagnosed metabolic diseases that may affect cardiovascular function and/or increase cardiovascular risk.
  • Any unstable medical condition.
  • Smoking > 5 cigarettes per day during the last 2 years.
  • Work involving night shifts (22:00 - 06:00 h) during the past 2 years.
  • Travel with > 6 time zone differences during the past 6 months.
  • Participation in any other study involving investigational or marketed products concomitantly or within 3 months prior to the screening visit.
  • Current participation in other clinical trials.

Additional Exclusion Criteria for RLS Patients

  • Exposure to dopaminergic drugs > 12 months during life time and/or > 1 week during the past 3 months and/or current or during the past month.
  • Exposure to other RLS relevant medication (such as opioids, antiepileptics, clonidine except hypnotics such as benzodiazepines) > 24 months during life time and/or > 1 week during the past 3 months and/or current intake.
  • Intake of hypnotics (such as benzodiazepines) during the past month.
  • Other significant sleep disorder except symptoms potentially related to RLS such as insomnia and daytime sleepiness.
  • Any contraindication or known hypersensitivity to dopaminergic drugs.

Additional Exclusion Criteria for Control Subjects

  • Any pharmacological treatment that may affect sleep and/or sleep related movement disorders during the last 3 months.
  • Any clinically significant sleep disorders according to the International Classification of Sleep Disorders (ICSD)12.
  • Increased daytime sleepiness as indicated by an Epworth Sleepiness Scale (ESS) score > 11.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02025608

Neurocenter of Southern Switzerland
Lugano, Ticino, Switzerland, 6903
Department of Neurology, Inselspital
Bern, Switzerland, 3010
Sponsors and Collaborators
Mauro Manconi
University Hospital Inselspital, Berne
Cardiocentro Ticino
Principal Investigator: Mauro Manconi, PhD, MD Neurocenter of Southern Switzerland
Principal Investigator: Claudio L.A. Bassetti, MD Department of Neurology, Inselspital
  More Information

Responsible Party: Mauro Manconi, Dr. med., Ospedale Regionale di Lugano Identifier: NCT02025608     History of Changes
Other Study ID Numbers: NSI.13.01
320030_144007 ( Other Grant/Funding Number: Swiss National Science Foundation )
Study First Received: December 23, 2013
Last Updated: January 23, 2017

Keywords provided by Mauro Manconi, Ospedale Regionale di Lugano:
Restless legs syndrome

Additional relevant MeSH terms:
Psychomotor Agitation
Restless Legs Syndrome
Pathologic Processes
Neurologic Manifestations
Nervous System Diseases
Psychomotor Disorders
Neurobehavioral Manifestations
Signs and Symptoms
Sleep Disorders, Intrinsic
Sleep Wake Disorders
Mental Disorders
Molecular Mechanisms of Pharmacological Action
Protective Agents
Physiological Effects of Drugs
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents processed this record on May 25, 2017